Company Profile
Resonance Health Limited, a healthcare technology and services company designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa.
Its business is organized into SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC).
Its portfolio also includes FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC, HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue, HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat, LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report, and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading, as well as phantoms comprising FerriScan, R2*/T2*, T1CMR, and T2CMR phantoms for the calibration of MRI machines.
Additionally, it operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors.
The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Incorporated in 1987, Resonance Health is headquartered in Burswood, Australia.